Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Phase I single ascending dose study of T-4288 in healthy adult subjects
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	interventional (treatment)
	Summary	To evaluate the pharmacokinetic profile, safety and tolerability
Details of study	Interventional drug name	T-4288
	Target illness	Japanese healthy adult male subjects
	Classification name (code) of the investigational drug	614
	Administration route	Oral Single Dose
	Control drug name	Placebo
	Classification name (code) of the investigational drug	-
	Administration route	Oral Single Dose
	Objectives of the study	To evaluate the pharmacokinetic profile, safety and tolerability
	Study phase	Phase I
	Study design	Randomized, Double-Blind, Placebo-Controlled study
	Inclusion Criteria	1. Japanese healthy male subjects between 20 and 55 years of age 2. BMI between 18.0 and 30.0 kg/ m^2 3. Understand the requirements of the study and voluntarily consent to participate in the study 4. Others
	Exclusion Criteria	1. Have a history or presence of clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition, which, in the opinion of the PI, would jeopardize the safety of the subject or impact the validity of the study results 2. Have a history of allergy to macrolide antibiotics 3. Have made a blood donation within 14 days prior to Day 1 dosing 4. Others
	Outcome	pharmacokinetic profile, safety and tolerability
	Study status	Completed
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn